Definium Therapeutics

Update in progress

DFTX (NasdaqGS)

Definium Therapeutics, Inc. is a clinical biopharmaceutical company focused on brain health disorders. Its lead candidates are DT120, in phase 3 for generalized anxiety and major depressive disorders, among other brain conditions; and DT402, the R-enantiomer of MDMA, in phase 2a for autism spectrum disorder. Formerly Mind Medicine (MindMed) Inc., it renamed to Definium Therapeutics, Inc. in January 2026 and is headquartered in New York, NY.